ArticleBlood neoplasia2026
Targeting ROR1 with KAN571C disrupts resistance networks in mantle cell lymphoma.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to Bruton tyrosine kinase (TK) and BCL2 inhibitors, such as ibrutinib (Ibru) and venetoclax (Ven), remains a major therapeutic challenge in mantle cell lymphoma (MCL), which limits treatment options. Receptor TK-like orphan receptor 1 (ROR1), aberrantly expressed in MCL and other malignancies but largely absent in normal adult tissues, has been implicated in tumor cell proliferation, survival, and migration. This study aimed to elucidate the mechanisms underlying Ibru and Ven resistance in MCL and to investigate the therapeutic potential of targeting ROR1 using the small-molecule inhibitor KAN571C in Ibru- and/or Ven-resistant MCL cell lines. Ibru-, Ven-, and Ibru + Ven (Double)-resistant models were generated from the JEKO-1, Granta-519, and Z138 MCL cell lines. The cytotoxic effects of Ibru, Ven, and KAN571C were assessed in both naive and drug-resistant models using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays. Western blotting was used to analyze downstream signaling alterations after exposure to KAN571C. KAN571C induced potent cytotoxicity in both naive and drug-resistant models, preferentially in Ven- and Ibru/Ven-resistant cells. Mechanistically, KAN571C dephosphorylated ROR1 at TK and proline-rich domains, suppressed downstream phosphatidylinositol 3-kinase/AKT and β-catenin signaling, and activated caspase-dependent apoptosis. Notably, long-term exposure (2 weeks) failed to establish KAN571C-resistant cell lines. Our findings identify ROR1 as a convergent mediator of resistance in MCL and highlight KAN571C as a potential therapeutic strategy to overcome treatment refractoriness.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.